NASDAQ: DMAADrugs Made In America Acquisition Corp Stock
$10.05+0.02 (+0.2%)
Updated Apr 21, 2025
DMAA Price
$10.05
Fair Value Price
N/A
Market Cap
$336.85M
52 Week Low
$9.95
52 Week High
$10.82
P/E
-335x
P/B
-1,375.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$279.85k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-3.25
Operating Cash Flow
-$172k
Beta
0.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMAA Overview
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMAA's potential to beat the market
- DMAA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
DMAA
RankedUnranked of 16
RankedUnranked of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.08 | C | |
| $10.09 | C | |
| $10.09 | C |
Be the first to know about important DMAA news, forecast changes, insider trades & much more!
DMAA News
Overview
Due Diligence Score
–
Industry Average (11)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMAA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMAA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DMAA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
DMAA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more DMAA due diligence checks available for Premium users.
Valuation
DMAA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-335x
Industry
-26.71x
Market
27.14x
DMAA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1,375.76x
Industry
-52.36x
DMAA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
DMAA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$550.8k
Liabilities
$795.7k
Debt to equity
-3.25
DMAA's short-term liabilities ($795.67k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMAA's short-term assets ($4.99k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMAA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMAA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
DMAA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMAA vs Shell Company Stocks
Drugs Made In America Acquisition Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.